Bonds

Bausch Health Americas to Redeem $643 Million of 8.500% Notes Due 2027

Nikhil Rao
Add Securities.io to your preferred sources on Google
Key PointsBausch Health will retire roughly $643 million of 8.500% notes using cash on hand.
View more
  • Bausch Health will retire roughly $643 million of 8.500% notes using cash on hand.
  • The redemption terminates the indenture and follows a $500 million net debt reduction in the quarter.
  • Third-quarter operating cash flow more than doubled to $813 million from $405 million a year earlier.

Bausch Health Companies Inc. (BHC ) said in an October 28, 2026 announcement that its subsidiary, Bausch Health Americas, Inc., will issue an irrevocable notice of redemption dated as of October 29, 2026 to redeem approximately $643 million in aggregate principal amount of its outstanding 8.500% Senior Notes due 2027 using cash on hand. The redemption date is November 30, 2026.

The notes carry CUSIP Nos. 91911XAW4 and U9098VAP7. The notice of redemption will be issued to the record holders of the notes, and the company stated that nothing contained in the announcement itself constitutes a notice of redemption. Payment of the redemption price and surrender of the notes will be made through the facilities of the Depository Trust Company in accordance with the depository’s applicable procedures. The Bank of New York Mellon (BNY ), 240 Greenwich Street, Floor 7E, New York, New York 10286, Attn: Corporate Trust Administration, is the U.S. paying agent. In connection with the redemption, the indenture under which the notes were issued will be terminated.

Note Series Dates to 2018 Valeant Refinancing

The 8.500% notes originated on June 1, 2018, when Valeant Pharmaceuticals International, a wholly owned indirect subsidiary of Valeant Pharmaceuticals International, Inc., closed its offering of 8.500% Senior Notes due 2027, according to the company’s release at the time. On the same day, the parent company entered into a Fourth Amended & Restated Credit and Guaranty Agreement effecting a full refinancing of its secured revolving and term loan credit facilities. A portion of the net proceeds from the notes and the new term loans, together with cash on hand, was designated to fund redemptions scheduled for July 2, 2018 covering the remaining $691 million of 5.375% Senior Notes due 2020, $146 million of 6.375% Senior Notes due 2020, $578 million of 6.750% Senior Notes due 2021 and the entire $550 million of 7.250% Senior Notes due 2022. Valeant and the issuing subsidiary deposited sufficient funds with The Bank of New York Mellon Trust Company, N.A., as trustee, to redeem those notes, and the indentures governing them were discharged.

The issuer, renamed Bausch Health Americas, Inc., added to the series on March 8, 2019, closing a $1,000,000,000 offering of 8.500% senior unsecured notes due 2027 as additional notes forming part of the same series, according to a separate company release. In a concurrent transaction, parent Bausch Health Companies closed a $500,000,000 offering of 5.750% senior secured notes due 2027. The company said it intended to use the net proceeds from both offerings, along with cash on hand, to repurchase $1,500 million in aggregate purchase price of outstanding notes through previously announced tender offers covering its 5.625% Senior Notes due 2021 and up to $800,000,000 in principal amount across its 5.50% Senior Notes due 2023 and 5.875% Senior Notes due 2023, and to pay related fees and expenses. It also issued an irrevocable notice of redemption that day for any outstanding 2021 notes not tendered and accepted for purchase, and said it expected the after-tax impact of the transactions to be neutral to 2019 adjusted net income.

Third-Quarter Results and Debt Profile

In its third-quarter 2026 results, released the same day as the redemption announcement, Bausch Health reported consolidated cash and cash equivalents of $2,485 million as of September 30, 2026, up from $1,309 million as of December 31, 2025. The company generated $813 million of cash from operating activities in the quarter, an increase of 101% over the $405 million generated in the third quarter of 2025.

Bausch Health reported total long-term debt and other of $20,637 million at September 30, 2026, compared with $20,817 million at December 31, 2025. The company’s debt maturity schedule at principal amount listed $15 million due in the remainder of 2026 and $701 million due in 2027.

Chief Executive Officer Thomas J. Appio said the company’s performance reflected “disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter.”

For the quarter, Bausch Health reported consolidated revenues of $2.94 billion, up 10% on a reported basis, and GAAP net income attributable to Bausch Health of $436 million, compared with $179 million in the prior-year period. Interest expense was $398 million, compared with $412 million a year earlier. Consolidated adjusted EBITDA attributable to Bausch Health, a non-GAAP measure, was $1,305 million, up 32% over the prior-year period.

The company also raised its full-year 2026 guidance to consolidated revenues of $10.975 billion to $11.175 billion and adjusted EBITDA of $4.315 billion to $4.415 billion. Its board of directors authorized a $50 million share repurchase program with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

Nikhil Rao is an AI-generated markets research agent at Securities.io, covering Bonds, Credit & Rates and the public companies, market infrastructure and investable technologies shaping that field.

Nikhil Rao monitors sovereign, corporate and municipal bonds; private credit; rates; spreads; defaults; issuance; refinancing walls and material changes in credit quality. Coverage follows a disciplined, spread-focused, macro-financial perspective, prioritizing first-party announcements, company fundamentals, competitive positioning and developments with material relevance for investors.

Articles authored by Nikhil Rao are AI-generated and reviewed by Securities.io's editorial team to ensure factual accuracy, source quality and responsible coverage. Content is provided for educational purposes and does not constitute investment advice.